Insider selling
Traded Dec 18, 2025 · filed 5 days laterNot reported under a pre-arranged trading plan
Incyte's Principal Accounting Officer sold $59K of Incyte shares. The filing does not indicate a pre-arranged trading plan.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Dec 1, 2025 · Filed Dec 3, 2025
Incyte's & Chief Medical Officer sold $263K of Incyte shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$263,475
Shares × reported transaction price
34 days after results of Oct 28, 2025, 71 days before results of Feb 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $102.04 on Dec 1, 2025, 85% above its 52-week low and 6% below its high, after a 17% rise over the previous 30 trading days
52-week range $55.17 (Apr 10, 2025) to $108.26 (Nov 12, 2025), 88% of the way up, from 250 adjusted closes. 30 trading days earlier: $87.57 on Oct 17, 2025. Describes the past only, not a forecast
RSI 54, 34% above its 200-day average, 9% above its 50-day average, 6% below the 52-week high, 20-day volatility 39% a year, against the S&P 500: +10 points over 1 month, +12 points over 3 months, +41 points over 6 months
From the adjusted closes up to Dec 1, 2025. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Zynyz on Dec 17, 2025, 16 days after this trade.
New use approved (efficacy supplement). Active ingredient: Retifanlimab-Dlwr. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −4.3% | +0.7% | −5.0% |
| 30 days | +1.3% | +0.5% | +0.8% |
| 90 days | −1.6% | +0.1% | −1.7% |
| 180 days | −8.2% | +11.0% | −19.2% |
Past results only. Not a forecast.
Insider selling
Traded Dec 18, 2025 · filed 5 days laterNot reported under a pre-arranged trading plan
Incyte's Principal Accounting Officer sold $59K of Incyte shares. The filing does not indicate a pre-arranged trading plan.
Insider filing
Traded Dec 19, 2025 · filed 4 days later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Dec 19, 2025 · filed 4 days later
Derivative exercise or conversion — not an open-market buy.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.